ProteanFect™
TuffCell Transfection Kit
Your solution for hard-to-transfect cells
A non-viral, non-liposomal, coacervate-based nucleic acid delivery platform based on mammalian endogenous protein, offering novel solution for efficient gene delivery.
Transfection Efficiency
Cytotoxicity
Payload Capacity
Protocol
A coacervate is a type of droplet-like structure formed when charged polymers (such as proteins, peptides, or nucleic acids) spontaneously separate from solution into a dense, liquid-rich phase, surrounded by a more dilute outer phase. This phenomenon is called liquid-liquid phase separation (LLPS).
What is ProteanFect?
A groundbreaking nucleic acid delivery system that leverages coacervate technology to achieve efficient gene delivery through non-viral, non-electroporation, and non-liposomal approaches.
How ProteanFect Works
ProteanFect forms nanoparticles that rapidly deliver gene cargo into cells, enabling efficient gene expression and safe degradation after delivery.
Why Choose ProteanFect™ TuffCell?
Revolutionary coacervate-based delivery platform offering unprecedented efficiency and safety for hard-to-transfect cells.
Novel Technology
Solution for Hard-to-Transfect Cells
Unlock the full potential of your research with reliable gene delivery into the hardest cells — from T cells and NK cells to neurons and stem cells. ProteanFect™ delivers where lipids fail and electroporation harms.
Primary Cells
Gentle Transfection on Cells
Preserve cell health and function with a protein-based system that minimizes toxicity, stress, and membrane disruption — ensuring your immune cells kill, your neurons fire, and your stem cells differentiate as nature intended.
High Efficiency
Versatility of Cargo Type
From mRNA and siRNA to large plasmids and multiplex CRISPR components, ProteanFect™ flexibly delivers a broad range of nucleic acids — giving you one solution for every experiment.
Available Product Kits
Choose from our range of ProteanFect™ kits optimized for different cell types and applications.
| SKU | Name | Cart |
|---|---|---|
| ProteanFect™ TuffCell Transfection Kit - 0.02 mL | ||
| ProteanFect™ TuffCell Transfection Kit - 0.1 mL | ||
| ProteanFect™ TuffCell Transfection Kit - 1.0 mL | ||
| ProteanFect™ TuffCell Mouse Immunocyte Transfection Kit - 0.02 mL | ||
| ProteanFect™ TuffCell Mouse Immunocyte Transfection Kit - 0.1 mL | ||
| ProteanFect™ TuffCell Mouse Immunocyte Transfection Kit - 1.0 mL |
Successfully Transfected Cell Types
Comprehensive list of cell lines and primary cells successfully transfected with ProteanFect™
| Cell Type | Tested Cargo | Transfection Efficiency | |
|---|---|---|---|
| Primary Cells | Human T Cells |
mRNA
siRNA
RNP
|
50-100% |
| Human B Cells |
mRNA
siRNA
RNP
|
20-75% | |
| Human Natural Killer Cells |
mRNA
siRNA
RNP
|
25-75% | |
| iPSCs (Induced Pluripotent Stem Cells) |
pDNA
mRNA
siRNA
RNP
|
50-100% | |
| HSCs (Human CD34+ Hematopoietic Stem Cells) |
mRNA
siRNA
RNP
|
50-100% | |
| UC-MSCs (Umbilical Cord Mesenchymal Stem Cells) |
mRNA
siRNA
|
50-100% | |
| Human Skin Fibroblasts |
pDNA
mRNA
siRNA
|
50-100% | |
| KSL (Mouse Hematopoietic Stem Cells) |
mRNA
siRNA
|
50-100% | |
| Mouse Neurons |
pDNA
mRNA
siRNA
|
10-50% | |
| Mouse Oligodendrocytes |
pDNA
mRNA
siRNA
|
50-100% | |
| Porcine Macrophages |
mRNA
siRNA
|
50-75% | |
| Bovine Fibroblasts |
mRNA
siRNA
|
50-100% | |
| M. rosenbergii Hemocytes |
mRNA
siRNA
|
25-75% | |
| Chicken Primordial Germ Cells |
mRNA
siRNA
RNP
|
25-100% | |
| L. crocea Mesenchymal Stem Cells |
mRNA
siRNA
|
25-50% | |
| Cell Type | Tested Cargo | Transfection Efficiency | |
|---|---|---|---|
| Cell Lines | Jurkat (Human T Cells) |
pDNA
mRNA
siRNA
RNP
|
50-100% |
| MOLT-16 (Human T-ALL Cells) |
mRNA
siRNA
|
10-30% | |
| Raji (Human B Cells) |
mRNA
siRNA
|
50-100% | |
| MEC-1 (Human B Cells) |
mRNA
siRNA
|
50-100% | |
| TMD8 (Human Diffuse Large B-Cell Lymphoma Cells) |
mRNA
siRNA
|
50-100% | |
| NK-92 (Human Natural Killer Cells) |
mRNA
siRNA
|
25-75% | |
| K562 (Human Chronic Myeloid Leukemia) |
pDNA
mRNA
siRNA
RNP
|
30-100% | |
| THP-1 (Human Monocytic Cells) |
mRNA
siRNA
|
50-100% | |
| Kasumi-1 (Human Acute Myeloid Leukemia) |
mRNA
siRNA
RNP
|
50-100% | |
| MDS-L (Human Leukemia Cells) |
mRNA
siRNA
|
50-100% | |
| U937 (Human Myeloid Leukemia) |
mRNA
siRNA
|
50-75% | |
| HL-60 (Human Promyelocytic Leukemia) |
mRNA
siRNA
|
50-100% | |
| HFF (Human Fibroblasts) |
mRNA
siRNA
RNP
|
50-100% | |
| LX-2 (Human Hepatic Stellate Cells) |
pDNA
mRNA
siRNA
|
50-100% | |
| HepG2 (Human Liver Carcinoma) |
pDNA
mRNA
siRNA
RNP
|
25-75% | |
| KYSE-510 (Human Esophageal Squamous Cell Carcinoma) |
mRNA
siRNA
|
50-100% | |
| Mum2B (Human Melanoma) |
mRNA
siRNA
|
50-100% | |
| H1-hESC (Human Embryonic Stem Cells) |
pDNA
mRNA
siRNA
|
50-100% | |
| U2OS (Human Osteosarcoma) |
pDNA
mRNA
siRNA
|
50-100% | |
| HT-29 (Human Colorectal Adenocarcinoma Cells) |
pDNA
mRNA
siRNA
|
50-100% | |
| 5637 (Human Bladder Carcinoma Cells) |
pDNA
mRNA
siRNA
RNP
|
50-100% | |
| HGC-27 (Human Gastric Carcinoma Cells) |
mRNA
siRNA
|
50-100% | |
| SH-SY5Y (Human Neuroblastoma Cells) |
pDNA
mRNA
siRNA
|
50-100% | |
| U251MG Cells (Human Glioblastoma Cells) |
mRNA
siRNA
|
50-100% | |
| HEK293 (Human Embryonic Kidney Cells) |
pDNA
mRNA
siRNA
RNP
|
50-100% | |
| Neuro 2A (Mouse Neuroblastoma Cells) |
pDNA
mRNA
siRNA
|
50-100% | |
| MC38 (Mouse Colon Adenocarcinoma Cells) |
mRNA
siRNA
|
25-75% | |
| RAW264.7 (Mouse Macrophages) |
mRNA
siRNA
|
50-80% | |
| LLC (Mouse Lewis Lung Carcinoma) |
pDNA
mRNA
siRNA
|
50-100% | |
| CH12 (Mouse Lymphoma Cells) |
mRNA
siRNA
|
50-100% | |
| BV-2 (Mouse Microglial Cells) |
mRNA
siRNA
|
25-50% | |
| C2C12 (Mouse Myoblasts) |
pDNA
mRNA
siRNA
|
50-100% | |
| B16 (Mouse Melanoma Cells) |
mRNA
siRNA
|
25-75% | |
| MH-S (Mouse Macrophages) |
mRNA
siRNA
|
25-50% | |
| MODE-K (Mouse Intestinal Epithelial Cells) |
mRNA
siRNA
|
50-100% | |
| MEF (Mouse Embryonic Fibroblasts) |
pDNA
mRNA
siRNA
|
25-100% | |
| 3T3 (Mouse Embryonic Fibroblasts) |
mRNA
siRNA
|
25-50% | |
| OLN93 (Rat Oligodendrocyte Cells) |
mRNA
siRNA
|
50-100% | |
| MDBK (Bovine Kidney Epithelial Cells) |
mRNA
siRNA
|
50-100% | |
| MAC-T (Bovine Mammary Epithelial Cells) |
mRNA
siRNA
|
50-100% | |
| COS-7 (Monkey Kidney Fibroblast-like Cells) |
pDNA
mRNA
siRNA
|
50-100% | |
| Cell Lines | Cargo Type |
|---|---|
| Human primary T cells |
mRNA
siRNA
|
| Human primary NK cells |
mRNA
siRNA
|
| Human primary monocytes |
mRNA
siRNA
|
| Human primary CD34+ hematopoietic stem cells |
mRNA
siRNA
|
| Mouse primary cardiomyocytes |
mRNA
siRNA
|
| Mouse primary neurons |
mRNA
siRNA
pDNA
|
| Jurkat T (human T lymphoblastic leukemia cells) |
mRNA
siRNA
pDNA
|
| SH-Sy5Y (human neuroblastoma cells) |
mRNA
siRNA
pDNA
|
Transfection Protocol for mRNA per well of 96-well plate
How ProteanFect™ Compares
See how ProteanFect™ TuffCell Transfection Kit stands against other leading transfection methods in the market.
Transfection Method Comparison
Comprehensive comparison of ProteanFect™ TuffCell with other popular transfection methods.
| Feature / Metric | ProTeanFect™ TuffCell | Lipid Reagents | Electroporation |
|---|---|---|---|
| Efficiency in Primary Cells | |||
| Cell Viability | |||
| Suspension Cells (e.g., Jurkat, K562) | |||
| Cargo Flexibility | |||
| Ease of Use / Workflow | |||
| Functional Preservation | |||
| Scalability | |||
| Safety / Biocompatibility | |||
| Best Use Case | Hard-to-transfect cells where viability matters most | Routine, easy-to-transfect adherent cell lines | Short-term high-efficiency delivery in difficult cells (sacrifice viability) |
Proven Performance in the Hardest Cells
ProteanFect™ delivers high efficiency in primary and suspension cells — including T cells, NK cells, neurons, and stem cells — where lipids fail and electroporation harms viability.
Gentle Yet Powerful Delivery
Unlike harsh or toxic alternatives, ProteanFect™ maintains cell health, phenotype, and function, enabling more biologically relevant results.
Versatility Without Complexity
A simple, scalable mix-and-go system that supports a wide range of nucleic acid cargos (mRNA, siRNA, plasmids, CRISPR), making it the go-to solution for diverse applications.
Case Studies
-
Key Performance Highlights of TT300007 in CD34+ Hematopoietic Stem Cells
Figure 1: ProteanFect achieves high transfection efficiency with mRNA in CD34+ hematopoietic stem cells without altering their differentiation -
Key Performance Highlights of TT300007 in Human Primary T Cells
Figure 2: ProteanFect achieves high transfection efficiency with mRNA in human primary T cells while maintaining an excellent safety profile -
Key Performance Highlights of TT300007 in NK Cells
Figure 3: ProteanFect achieves high transfection efficiency with mRNA in NK cells -
Key Performance Highlights of TT300007 in Human Primary T Cells
Figure 4: ProteanFect enables high-efficiency gene editing in human primary T cells via co-delivery of Cas9 mRNA and sgRNA -
Key Performance Highlights of TT300007 in Jurkat T Cells
Figure 5: ProteanFect achieves high transfection efficiency with pDNA/mRNA in Jurkat T Cells -
Key Performance Highlights of TT300007 in Jurkat T cells
Figure 6: ProteanFect achieves high transfection efficiency of high molecular weight nucleic acids or co-transfection of multiple nucleic acids in Jurkat T cells -
Key Performance Highlights of TT300007 in K562 Cells
Figure 7: ProteanFect achieves high transfection efficiency in K562 cells -
Key Performance Highlights of TT300007 in Jurkat T Cells
Figure 8: ProteanFect enables high-efficiency gene editing in Jurkat T Cells via co-delivery of Cas9 mRNA and sgRNA -
Key Performance Highlights of TT300008 in Mouse Primary T Cells
Figure 9: ProteanFect achieves high transfection efficiency with mRNA in mouse primary T cells while maintaining an excellent safety profile -
Key Performance Highlights of TT300008 in Mouse Primary NK Cells
Figure 10: ProteanFect achieves high tansfection efficiency with mRNA in mouse primary NK cells -
Key Performance Highlights of TT300008 in Mouse Primary T Cells
Figure 11: ProteanFect enables high-efficiency gene editing in mouse primary T cells via co-delivery of Cas9 protein and sgRNA (RNP)
Recent Citations for ProteanFect™
|
1 H2A.Z primes an epigenetic landscape for memory CD8+ T cell recall response Published in Nature Communications |
View Publication |
|
2 CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer Published in Nature Cell Biology |
View Publication |
|
3 High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming Published in Signal Transduction and Targeted Therapy |
View Publication |